Patent ID: 8394822

Claim:
A method for the treatment of a disorder for which the administration of a selective MEK inhibitor is indicated which comprises administering to a patient in need of such treatment an effective amount of a compound or a pharmaceutically acceptable salt, or N-oxide thereof of Formula I: wherein R 1 is hydrogen, halogen or C 1-6 alkyl; R 2 is halogen or C 1-6 alkyl; R 3 is hydrogen, cyano, —CO 2 R a , —CONR b R c or —CON(OR b )R c ; R a is C 1-6 alkyl; R b is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted C 3-7 cycloalkyl(C 1-6 )alkyl, optionally substituted aryl, optionally substituted aryl(C 1-6 )alkyl, optionally substituted C 3-7 heterocycloalkyl, optionally substituted C 3-7 heterocycloalkyl(C 1-6 )alkyl, optionally substituted heteroaryl or optionally substituted heteroaryl(C 1-6 )alkyl; R c is hydrogen or C 1-6 alkyl optionally substituted with one or more hydroxyl groups; or R b and R c are taken together with the nitrogen atom to which they are attached to form a cyclic group selected from optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted morpholinyl, optionally substituted thiomorpholinyl, optionally substituted piperazinyl, optionally substituted homopiperidinyl, optionally substituted homomorpholinyl and optionally substituted homopiperazinyl.